|
| 产品描述 |
| Alisertib, also known as MLN8237, is a second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Aurora kinase inhibitor MLN8237 binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation. |
| 化学结构 |
 |
| 化学名称 |
| 4-((9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl)amino)-2-methoxybenzoic acid |
| SMILES Code |
| O=C(O)C1=CC=C(NC2=NC=C3C(C4=CC=C(Cl)C=C4C(C5=C(OC)C=CC=C5F)=NC3)=N2)C=C1OC |
| 基本信息 |
产品编号:XM407
产品名称:Alisertib (MLN8237)
别名:MLN8237; MLN-8237; MLN 8237; alisertib.
CAS#:1028486-01-2
分子式:C27H20ClFN4O4
精确分子量:518.11571
分子量:518.9
|
| 物化性质 |
外观: 白色或类白色固体粉末
纯度: >98%
运输信息: 非危险化学品，适于常温或冰袋运输。
储存条件: 低温，干燥，避光。
溶解性: 溶于DMSO, 不溶于水
储存期限:3年 -20℃固体储存
2 年 -80℃ 溶液储存 |
该产品只供科研使用，不能给病人提供。
|
|
|
